Reports Q1 revenue $14.5B, consensus $13.8B. Dr. Albert Bourla, Chairman and CEO of Pfizer (PFE): “We’re off to a strong start in 2026, and it reinforces our confidence that we will successfully navigate this defining period for Pfizer. Our R&D pipeline is advancing on multiple fronts – with positive Phase 3 readouts and encouraging mid-stage results building meaningful momentum – and I’m particularly encouraged by what we’re seeing in oncology and obesity, two areas where I believe Pfizer is positioned to lead.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- These Are the Stocks Reporting Earnings Today – May 5, 2026
- Notable companies reporting before tomorrow’s open
- Guardant Health receives FDA approval for Guardant360 CDx
- Options Volatility and Implied Earnings Moves This Week, May 04 – May 07, 2026
- Pfizer Reports Q1 Earnings Tomorrow. What Shareholders Should Expect.